Q2 Earnings Estimate for KROS Issued By Leerink Partnrs

Keros Therapeutics, Inc. (NASDAQ:KROS) – Equities researchers at Leerink Partnrs issued their Q2 2025 earnings per share (EPS) estimates for Keros Therapeutics in a report issued on Thursday, February 27th. Leerink Partnrs analyst T. Smith forecasts that the company will post earnings per share of ($1.02) for the quarter. The consensus estimate for Keros Therapeutics’ current full-year earnings is ($4.74) per share. Leerink Partnrs also issued estimates for Keros Therapeutics’ Q3 2025 earnings at ($0.66) EPS and Q4 2025 earnings at ($0.63) EPS.

KROS has been the subject of a number of other research reports. Scotiabank dropped their target price on Keros Therapeutics from $44.00 to $41.00 and set a “sector outperform” rating for the company in a report on Thursday, January 16th. BTIG Research lowered Keros Therapeutics from a “buy” rating to a “neutral” rating in a research report on Thursday, December 12th. Truist Financial decreased their target price on Keros Therapeutics from $100.00 to $43.00 and set a “buy” rating for the company in a research report on Monday, December 23rd. Piper Sandler reduced their price target on Keros Therapeutics from $40.00 to $15.00 and set an “overweight” rating for the company in a research report on Friday, January 17th. Finally, Wells Fargo & Company reduced their target price on Keros Therapeutics from $28.00 to $26.00 and set an “overweight” rating on the stock in a research report on Thursday. Six analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $42.33.

Keros Therapeutics Trading Up 0.6 %

Shares of KROS opened at $11.08 on Friday. The business’s 50 day moving average is $12.52 and its 200 day moving average is $39.56. The company has a market capitalization of $448.82 million, a PE ratio of -2.13 and a beta of 1.39. Keros Therapeutics has a 12-month low of $9.77 and a 12-month high of $73.00.

Keros Therapeutics (NASDAQ:KROS) last announced its earnings results on Wednesday, February 26th. The company reported ($1.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.36) by $0.22. Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. The business had revenue of $3.04 million for the quarter, compared to analysts’ expectations of $37.32 million.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. FMR LLC grew its holdings in shares of Keros Therapeutics by 3.8% during the 3rd quarter. FMR LLC now owns 4,899,134 shares of the company’s stock worth $284,493,000 after purchasing an additional 179,374 shares during the period. Vanguard Group Inc. raised its position in shares of Keros Therapeutics by 5.4% during the 4th quarter. Vanguard Group Inc. now owns 1,957,109 shares of the company’s stock valued at $30,981,000 after acquiring an additional 100,691 shares in the last quarter. Alkeon Capital Management LLC raised its position in shares of Keros Therapeutics by 18.7% during the 3rd quarter. Alkeon Capital Management LLC now owns 1,897,601 shares of the company’s stock valued at $110,194,000 after acquiring an additional 298,694 shares in the last quarter. Braidwell LP raised its position in shares of Keros Therapeutics by 167.9% during the 4th quarter. Braidwell LP now owns 1,894,439 shares of the company’s stock valued at $29,989,000 after acquiring an additional 1,187,199 shares in the last quarter. Finally, Darwin Global Management Ltd. raised its position in shares of Keros Therapeutics by 10.7% during the 4th quarter. Darwin Global Management Ltd. now owns 1,687,135 shares of the company’s stock valued at $26,707,000 after acquiring an additional 163,403 shares in the last quarter. 71.56% of the stock is currently owned by institutional investors and hedge funds.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.